Compare ANIP & TIGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIP | TIGR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | N/A | 2019 |
| Metric | ANIP | TIGR |
|---|---|---|
| Price | $80.96 | $9.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $102.14 | $14.20 |
| AVG Volume (30 Days) | 438.9K | ★ 4.0M |
| Earning Date | 11-07-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 328.15 |
| EPS | ★ 1.67 | 0.82 |
| Revenue | ★ $826,880,000.00 | $489,538,356.00 |
| Revenue This Year | $43.41 | $62.71 |
| Revenue Next Year | $9.66 | $6.55 |
| P/E Ratio | $49.04 | ★ $11.29 |
| Revenue Growth | 48.87 | ★ 76.50 |
| 52 Week Low | $52.50 | $5.64 |
| 52 Week High | $99.50 | $13.55 |
| Indicator | ANIP | TIGR |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 49.97 |
| Support Level | $80.57 | $9.09 |
| Resistance Level | $83.60 | $9.47 |
| Average True Range (ATR) | 2.45 | 0.39 |
| MACD | 0.15 | 0.12 |
| Stochastic Oscillator | 36.70 | 88.38 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.